|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
EP0382781B1
(en)
|
1987-10-23 |
1993-09-29 |
Genetics Institute, Inc. |
Composition for treating cancers characterized by over-expression of the c-fms proto-oncogene
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
US6713610B1
(en)
|
1990-01-12 |
2004-03-30 |
Raju Kucherlapati |
Human antibodies derived from immunized xenomice
|
|
US5877397A
(en)
|
1990-08-29 |
1999-03-02 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5874299A
(en)
|
1990-08-29 |
1999-02-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US6255458B1
(en)
|
1990-08-29 |
2001-07-03 |
Genpharm International |
High affinity human antibodies and human antibodies against digoxin
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US6300129B1
(en)
|
1990-08-29 |
2001-10-09 |
Genpharm International |
Transgenic non-human animals for producing heterologous antibodies
|
|
EP0668914B1
(en)
|
1992-06-09 |
2000-08-16 |
Chiron Corporation |
Crystallization of m-csf
|
|
US20020193575A1
(en)
|
1993-09-07 |
2002-12-19 |
Smithkline Beecham P.L.C. |
Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
|
|
JPH10218791A
(ja)
|
1997-01-31 |
1998-08-18 |
Toagosei Co Ltd |
慢性関節リウマチ治療薬
|
|
US6972323B1
(en)
|
1997-04-01 |
2005-12-06 |
Sankyo Company, Limited |
Anti-Fas antibodies
|
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
|
WO1999029345A1
(en)
|
1997-12-05 |
1999-06-17 |
La Jolla Institute For Experimental Medicine |
Inhibition of tumor growth by macrophage intervention
|
|
CA2348292A1
(en)
|
1998-10-30 |
2000-05-11 |
Takeda Chemical Industries, Ltd. |
Betacellulin protein-containing preparation
|
|
WO2000067796A1
(en)
|
1999-05-07 |
2000-11-16 |
Genentech, Inc. |
Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
|
|
WO2001030381A2
(de)
|
1999-10-28 |
2001-05-03 |
Hofbauer, Reinhold |
Verwendung von csf-1-inhibitoren
|
|
WO2001034177A2
(en)
|
1999-11-08 |
2001-05-17 |
The Government Of The United States Of America, A S Represented By The Secretary, Department Of Hea Lth & Human Services, The National Institutes Of Health |
Method of treating a viral infection using antagonists of macrophage colony stimulating factor
|
|
US7108852B2
(en)
|
2000-03-20 |
2006-09-19 |
Warner-Lambert Company Llc |
Methods of treating inflammation using antibodies to M-CSF
|
|
US7455836B2
(en)
|
2000-05-08 |
2008-11-25 |
The University Of Melbourne |
Method of treatment and agents useful for same
|
|
US6773895B2
(en)
|
2000-09-01 |
2004-08-10 |
Boehringer Ingelheim Pharma Kg |
Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
|
|
US7247618B2
(en)
|
2001-04-30 |
2007-07-24 |
Tripathi Rajavashisth |
Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
|
|
CA2450793A1
(en)
|
2001-06-20 |
2002-12-27 |
Prochon Biotech Ltd. |
Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
|
|
DE60332483D1
(de)
|
2002-11-15 |
2010-06-17 |
Novartis Vaccines & Diagnostic |
Methoden zur verhinderung und behandlung von krebs-metastasierung und mit krebs-metastasierung einhergehendem knochenverlust
|
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
|
CA2541651C
(en)
|
2003-10-22 |
2011-05-24 |
Keck Graduate Institute |
Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
|
|
GB0325836D0
(en)
|
2003-11-05 |
2003-12-10 |
Celltech R&D Ltd |
Biological products
|
|
JP2007524671A
(ja)
|
2004-01-21 |
2007-08-30 |
カイロン コーポレイション |
Ｍ−ｃｓｆムテインおよびその使用
|
|
CA2565974A1
(en)
|
2004-05-14 |
2005-12-01 |
Receptor Biologix, Inc. |
Cell surface receptor isoforms and methods of identifying and using the same
|
|
EP2479277B1
(en)
|
2004-07-22 |
2015-09-02 |
Five Prime Therapeutics, Inc. |
Use of MGD-CSF in a method of treatment of Alzheimer's disease.
|
|
WO2006076288A2
(en)
|
2005-01-11 |
2006-07-20 |
Five Prime Therapeutics, Inc. |
Dna constructs for long-term expression of intravascularly injected naked dna
|
|
CA2589895A1
(en)
|
2005-01-27 |
2006-08-03 |
Five Prime Therapeutics, Inc. |
Leader sequences for directing secretion of polypeptides and methods for production thereof
|
|
US8003108B2
(en)
|
2005-05-03 |
2011-08-23 |
Amgen Inc. |
Sclerostin epitopes
|
|
EP1945662A2
(en)
|
2005-11-10 |
2008-07-23 |
Receptor Biologix, Inc. |
Methods for production of receptor and ligand isoforms
|
|
WO2007075933A2
(en)
|
2005-12-21 |
2007-07-05 |
Cell Signaling Technology, Inc. |
Translocation and mutant csf1r kinase in human leukemia
|
|
CN101379400A
(zh)
|
2005-12-22 |
2009-03-04 |
诺华有限公司 |
可溶性人m-csf受体及其应用
|
|
CN101534858A
(zh)
|
2006-01-05 |
2009-09-16 |
诺华有限公司 |
预防和治疗癌症转移和癌症转移相关性骨丢失的方法
|
|
WO2007130646A2
(en)
|
2006-05-04 |
2007-11-15 |
The Rockefeller University |
Hcv coreceptor and methods of use thereof
|
|
US7833789B2
(en)
|
2006-08-01 |
2010-11-16 |
Fondazione Centro San Raffaele Del Monte Tabor |
Monocyte cell
|
|
JP2010510219A
(ja)
|
2006-11-17 |
2010-04-02 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
アミロイド関連障害を処置するためのコロニー刺激因子の全身投与
|
|
US7919594B2
(en)
|
2007-02-14 |
2011-04-05 |
Vaccinex, Inc. |
Human anti-CD100 antibodies
|
|
WO2008124858A2
(en)
|
2007-04-11 |
2008-10-23 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. |
Targeted receptor
|
|
WO2008150383A1
(en)
|
2007-05-30 |
2008-12-11 |
Albert Einstein College Of Medicine Of Yeshiva University |
Csf-1r mutants
|
|
PL2188313T3
(pl)
|
2007-08-21 |
2018-04-30 |
Amgen, Inc. |
Białka wiążące ludzki antygen c-fms
|
|
US7981415B2
(en)
|
2007-09-07 |
2011-07-19 |
Cisthera, Inc. |
Humanized PAI-1 antibodies
|
|
WO2009058968A2
(en)
|
2007-10-31 |
2009-05-07 |
Janssen Pharmaceutica N.V. |
Biomarker for assessing response to fms treatment
|
|
EP2241333A1
(en)
|
2007-12-12 |
2010-10-20 |
National Cancer Center |
Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
|
|
BRPI0909044B8
(pt)
|
2008-03-14 |
2021-05-25 |
Transgene Sa |
anticorpo que se liga especificamente ao csf-1r humano,composição farmacêutica e uso dos mesmos
|
|
US8470977B2
(en)
|
2008-03-14 |
2013-06-25 |
Transgene S.A. |
Antibody against the CSF-1R
|
|
WO2010062399A2
(en)
|
2008-11-26 |
2010-06-03 |
Five Prime Therapeutics, Inc. |
Csf1r extracellular domain fusion molecules and treatments using same
|
|
US8183207B2
(en)
|
2008-11-26 |
2012-05-22 |
Five Prime Therapeutics, Inc. |
Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
|
|
ES2722300T3
(es)
|
2009-12-10 |
2019-08-09 |
Hoffmann La Roche |
Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
|
|
JP5989547B2
(ja)
|
2010-03-05 |
2016-09-07 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
ヒトｃｓｆ−１ｒに対する抗体及びその使用
|
|
US9169323B2
(en)
|
2010-03-05 |
2015-10-27 |
Hoffmann-La Roche Inc. |
Antibodies against human CSF-1R
|
|
AR080698A1
(es)
|
2010-04-01 |
2012-05-02 |
Imclone Llc |
Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
|
|
HRP20190047T1
(hr)
*
|
2010-05-04 |
2019-02-22 |
Five Prime Therapeutics, Inc. |
Protutijela koja se vežu na csf1r
|
|
TW201307845A
(zh)
|
2010-12-13 |
2013-02-16 |
Novartis Ag |
預測方法及利用ｉｌ－１７拮抗劑治療關節炎的方法
|
|
WO2013057281A2
(en)
|
2011-10-21 |
2013-04-25 |
Transgene Sa |
Modulation of macrophage activation
|
|
US20140288279A1
(en)
|
2011-10-21 |
2014-09-25 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
M-DC8+ Monocyte Depleting Agent for the Prevention or the Treatment of a Condition Associated with a Chronic Hyperactivation of the Immune System
|
|
RU2670743C9
(ru)
*
|
2012-05-11 |
2018-12-19 |
Файв Прайм Терапьютикс, Инк. |
Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
|
|
CN107759690A
(zh)
*
|
2012-08-31 |
2018-03-06 |
戊瑞治疗有限公司 |
用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
|
|
EP3212670B1
(en)
*
|
2014-10-29 |
2020-12-23 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer
|